Walleye Capital LLC Akebia Therapeutics, Inc. Transaction History
Walleye Capital LLC
- $24 Billion
- Q3 2025
A detailed history of Walleye Capital LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 152,953 shares of AKBA stock, worth $260,020. This represents 0.0% of its overall portfolio holdings.
Number of Shares
152,953
Previous 214,817
28.8%
Holding current value
$260,020
Previous $781,000
47.25%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding AKBA
# of Institutions
189Shares Held
121MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...